- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07937293
Association Between Intravenous Ferric Carboxymaltose Before Electrical Cardioversion and One-Year Atrial Fibrillation Recurrence in Patients With Heart Failure and Iron Deficiency
This study included 100 patients with persistent AF, heart failure (left ventricular ejection fraction 30-60%), and iron deficiency who underwent successful electrical cardioversion. Iron deficiency was defined as ferritin <100 ng/mL or 100-299 ng/mL with transferrin saturation <20%. Fifty patients received 1000 mg intravenous FCM immediately before cardioversion, while 50 served as controls. The primary endpoint was AF recurrence within 12 months.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Bursa, Turkey (Türkiye)
- Bursa Yüksek İhtisas
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Heart failure and atrial fibrillation patients with iron deficiency.
Description
Inclusion Criteria:
- Patients presenting to the cardiology clinic with atrial fibrillation (AF) for whom a rhythm-control strategy was selected and whose medical records contained complete clinical data.
- Patients with persistent atrial fibrillation.
- Patients aged 18-80 years.
- Patients with hemoglobin levels <13 g/dL in men or <12 g/dL in women, and serum ferritin levels <100 µg/L or ferritin levels of 100-300 µg/L with transferrin saturation (TSAT) <20%.
- Patients with a left ventricular ejection fraction (LVEF) between 30% and 60%.
- Patients who underwent successful electrical cardioversion.
Exclusion Criteria:
- Patients with a history of valvular heart surgery.
- Patients with a left ventricular ejection fraction <30%.
- Patients with rheumatological diseases.
- Patients with severe valvular heart disease.
- Patients with thyroid dysfunction.
- Patients with a history of myocardial infarction within the preceding 3 months.
- Patients with hemoglobin levels <8 g/dL.
- Patients who experienced an acute bleeding event within the preceding 3 months.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: OTHER
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Atrial Fibrillation Recurrence
Time Frame: one year
|
one year
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- 1. Hanna Rivero N, Tu SJ, Elliott AD, Pitman BM, Gallagher C, Lau DH, Sanders P, Wong CX. Anemia and iron deficiency in patients with atrial fibrillation. BMC Cardiovasc Disord. 2022;22:204. doi:10.1186/s12872-022-02646-5. 2. Mohamed AA, et al. Prognostic implications of iron deficiency in patients with heart failure. Heart. 2025;111:609 615. doi:10.1136/heartjnl-2024-324610. 3. Masini G, Graham FJ, Pellicori P, Cleland JGF, Cuthbert JJ, Kazmi S, et al. Intravenous iron for heart failure, iron deficiency definitions, and treatments. Eur J Heart Fail. 2023;25:528 537. doi:10.1002/ejhf.2947. 4. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599 3726. doi:10.1093/eurheartj/ehab368. 5. Barutcu C, Kıvrak Z. Iron deficiency and anemia in heart failure: prevalence, prognosis and treatment. Turk J Health Sci Life. 2021;4(3):101 105.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IV FCM and AF Recurrence
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
"Data will be made available upon reasonable request."
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.